HOME ABOUT US ADVERTISE SUBSCRIBE SITE MAP HELP CONTACT WORK FOR US  
Tuesday
7 September 2010
Make BTN my HomePage 
 







OPINION: Patient safety should be priority in stem cell decisions


STEM cell treatments have become one of the great medical promises of the age. But even though most of the treatments now being offered commercially are unproven, Australians are flocking to overseas stem cell “clinics” in search of a miracle cure. The Australian Stem Cell Centre’s Dr Kirsten Herbert sounds a warning to the local industry and to journalists covering the subject.



You are not logged in or not authorised to view this page.

Get Your FREE 30 Day Trial Now!

First Name
Last Name
Phone
Email Address
Confirm Email

OR

Members Login Here

Email Address
Password
 

  • Note: Cookies must be enabled to log in
  • Forgotten Your Password? Click here
  • Having problems? View our help page here.

Click here to read the rest of today's news stories.



 
RELATED LINKS

[COMPANY]
-AUSTRALIAN STEM CELL CENTRE
[SECTION]
-Industry Issues
-Health Biotech
-General
[REGION]
-Australia
[RELATED STORY]
-OPINION: An inside guide to a successful biotech IPO
-OPINION: R&D tax credit bill creates new barriers for biotechs




Company Search




Story Search

Advanced Search

UPCOMING
EVENTS
ABIC 2010 - Bridging Biology and Business
14th International Biotechnology Symposium & Exhibition 2010
BIO India Partnering Conference 2010
OZBIO2010
2010 Livestock Biotech Summit
BioPartnering Europe
  View all events


TODAY'S NEWS

Broadvector prepares $24.5M bang


Bio People: Australia, Research Australia, KarmelSonix and more *UPDATED*


In Silico: Is the IPO window cracking open?


Capital Briefs: Select, Helicon, PharmaNet and more


Avexa-Calzada rebuffed or engaged?


Bio Briefs: Genesis, Epichem, Sirtex and more


HealthLinx breaches rule *UPDATED*


Pipeline Progress: QRxPharma, Tyrian, Prana and more


Market Pulse: Gaining amid uncertainty


Avexa bioadvisors on board